CA2626623C - Methode d'inhibition de la kinase flt3 - Google Patents
Methode d'inhibition de la kinase flt3 Download PDFInfo
- Publication number
- CA2626623C CA2626623C CA2626623A CA2626623A CA2626623C CA 2626623 C CA2626623 C CA 2626623C CA 2626623 A CA2626623 A CA 2626623A CA 2626623 A CA2626623 A CA 2626623A CA 2626623 C CA2626623 C CA 2626623C
- Authority
- CA
- Canada
- Prior art keywords
- mmol
- carboxylic acid
- cyano
- cyclohex
- imidazole
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 C*(C)CC(*(CC1)CCC1c1ccc(C)c(*2=CCCC*2)c1)O Chemical compound C*(C)CC(*(CC1)CCC1c1ccc(C)c(*2=CCCC*2)c1)O 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Materials For Medical Uses (AREA)
Abstract
L'invention porte sur une méthode de réduction ou d'inhibition de l'activité de kinase du récepteur FLT3 dans une cellule ou un patient, pour prévenir ou traiter chez un patient les troubles de prolifération cellulaire et/ou liés au FLT3, en utilisant le composé de l'invention (l) ou un de ses solvates, hydrate, tautomère ou sel pharmacocompatible. L'invention porte également sur des méthodes de traitement d'états tels que le cancer ou d'autres troubles de prolifération cellulaire.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US72768705P | 2005-10-18 | 2005-10-18 | |
US60/727,687 | 2005-10-18 | ||
PCT/US2006/060028 WO2007048088A2 (fr) | 2005-10-18 | 2006-10-17 | Methode d'inhibition de la kinase flt3 |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2626623A1 CA2626623A1 (fr) | 2007-04-26 |
CA2626623C true CA2626623C (fr) | 2016-08-30 |
Family
ID=37864477
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2626623A Expired - Fee Related CA2626623C (fr) | 2005-10-18 | 2006-10-17 | Methode d'inhibition de la kinase flt3 |
Country Status (19)
Country | Link |
---|---|
US (1) | US7795279B2 (fr) |
EP (1) | EP1951234A2 (fr) |
JP (2) | JP2009511628A (fr) |
KR (1) | KR101443651B1 (fr) |
CN (1) | CN101340909B (fr) |
AU (1) | AU2006304897B2 (fr) |
BR (1) | BRPI0617489A2 (fr) |
CA (1) | CA2626623C (fr) |
CR (1) | CR9984A (fr) |
EA (1) | EA200801118A1 (fr) |
EC (1) | ECSP088387A (fr) |
GT (1) | GT200800042A (fr) |
IL (1) | IL190727A (fr) |
NO (1) | NO20082223L (fr) |
NZ (1) | NZ595182A (fr) |
SV (1) | SV2008002880A (fr) |
UA (1) | UA94719C2 (fr) |
WO (1) | WO2007048088A2 (fr) |
ZA (1) | ZA200804253B (fr) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6846630B2 (en) * | 1996-10-18 | 2005-01-25 | Takara Shuzo Co., Ltd. | Nucleic acid encoding receptor type protein kinase |
ES2611604T3 (es) * | 2004-10-22 | 2017-05-09 | Janssen Pharmaceutica Nv | Inhibidores de la c fms quinasa |
US20060281788A1 (en) * | 2005-06-10 | 2006-12-14 | Baumann Christian A | Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor |
AU2006304897B2 (en) * | 2005-10-18 | 2012-07-12 | Janssen Pharmaceutica N.V. | Method of inhibiting FLT3 kinase |
CN101454325A (zh) * | 2006-03-09 | 2009-06-10 | 法马科皮亚公司 | 用于治疗代谢性疾病的8-杂芳基嘌呤mnk2抑制剂 |
EP2021335B1 (fr) * | 2006-04-20 | 2011-05-25 | Janssen Pharmaceutica N.V. | Composés hétérocycliques inhibiteurs de c-fms kinase |
AU2007240400B2 (en) * | 2006-04-20 | 2013-08-22 | Janssen Pharmaceutica N.V. | Method of inhibiting C KIT kinase |
MX2008013529A (es) | 2006-04-20 | 2009-01-15 | Janssen Pharmaceutica Nv | Inhibidores de c-fms cinasa. |
US8697716B2 (en) | 2006-04-20 | 2014-04-15 | Janssen Pharmaceutica Nv | Method of inhibiting C-KIT kinase |
JO3240B1 (ar) * | 2007-10-17 | 2018-03-08 | Janssen Pharmaceutica Nv | c-fms مثبطات كيناز |
EP2521782B1 (fr) | 2010-01-05 | 2019-04-10 | INSERM - Institut National de la Santé et de la Recherche Médicale | Antagonistes du récepteur flt3 pour le traitement ou la prévention de troubles de la douleur |
WO2011113041A2 (fr) * | 2010-03-12 | 2011-09-15 | The Johns Hopkins University | Neutralisation de ligand de flt3 comme thérapie de la leucémie |
JP6046728B2 (ja) | 2011-09-30 | 2016-12-21 | オンコデザイン エス.ア. | 大環状flt3キナーゼ阻害剤 |
JOP20180012A1 (ar) | 2012-08-07 | 2019-01-30 | Janssen Pharmaceutica Nv | عملية السلفنة باستخدام نونافلوروبوتانيسولفونيل فلوريد |
ES2608628T3 (es) | 2012-08-07 | 2017-04-12 | Janssen Pharmaceutica Nv | Procedimiento para la preparacion de derivados de ester heterociclicos |
CN104370880A (zh) * | 2013-01-24 | 2015-02-25 | 韩冰 | 一类蛋白酶抑制剂及其制备方法和用途 |
GB201311891D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compound |
GB201311888D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
SG11201600504TA (en) | 2013-07-22 | 2016-02-26 | Actelion Pharmaceuticals Ltd | 1-(piperazin-1-yl)-2-([1,2,4]triazol-1-yl)-ethanone derivatives |
CN107001283B (zh) | 2014-07-31 | 2021-05-25 | 国家健康与医学研究院 | Flt3受体拮抗剂 |
AR103399A1 (es) | 2015-01-15 | 2017-05-10 | Actelion Pharmaceuticals Ltd | Derivados de (r)-2-metil-piperazina como moduladores del receptor cxcr3 |
ES2709985T3 (es) | 2015-01-15 | 2019-04-22 | Idorsia Pharmaceuticals Ltd | Derivados de hidroxialquil-piperazina como moduladores del receptor CXCR3 |
EP3254698A1 (fr) | 2016-06-08 | 2017-12-13 | Universite De Montpellier | Inhibiteur du récepteur flt3 à faible dose pour le traitement d'une douleur neuropathique |
WO2018118598A1 (fr) * | 2016-12-23 | 2018-06-28 | Arvinas, Inc. | Composés et procédés pour la dégradation ciblée de polypeptides de kinase du foie fœtal |
AU2018269678A1 (en) | 2017-05-17 | 2019-12-12 | Biodol Therapeutics | FLT3 inhibitors for improving pain treatments by opioids |
US11331313B2 (en) | 2017-05-22 | 2022-05-17 | Whitehead Institute For Biomedical Research | KCC2 expression enhancing compounds and uses thereof |
US11285131B2 (en) | 2017-08-04 | 2022-03-29 | Merck Sharp & Dohme Corp. | Benzo[b]thiophene STING agonists for cancer treatment |
AU2018311965A1 (en) | 2017-08-04 | 2020-02-13 | Merck Sharp & Dohme Llc | Combinations of PD-1 antagonists and benzo[b]thiophene sting antagonists for cancer treatment |
WO2019057649A1 (fr) | 2017-09-19 | 2019-03-28 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Méthodes et compositions pharmaceutiques pour le traitement de la leucémie myéloïde aiguë |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2131528C (fr) | 1992-03-05 | 2004-07-13 | Philip E. Thorpe | Agents diagnostiques et/ou therapeutiques cibles pour les cellules endotheliales neovasculaires |
US5474765A (en) | 1992-03-23 | 1995-12-12 | Ut Sw Medical Ctr At Dallas | Preparation and use of steroid-polyanionic polymer-based conjugates targeted to vascular endothelial cells |
JP4926320B2 (ja) | 1999-04-28 | 2012-05-09 | ボード・オブ・リージエンツ,ザ・ユニバーシテイ・オブ・テキサス・システム | Vegfの選択的阻害による癌処置のための組成物および方法 |
US6852752B2 (en) * | 1999-12-17 | 2005-02-08 | Vicuron Pharmaceuticals Inc. | Urea compounds, compositions and methods of use and preparation |
DE19962924A1 (de) | 1999-12-24 | 2001-07-05 | Bayer Ag | Substituierte Oxazolidinone und ihre Verwendung |
GB0005357D0 (en) * | 2000-03-06 | 2000-04-26 | Smithkline Beecham Plc | Compounds |
US6656942B2 (en) | 2000-10-17 | 2003-12-02 | Merck & Co., Inc. | Orally active salts with tyrosine kinase activity |
AR035885A1 (es) | 2001-05-14 | 2004-07-21 | Novartis Ag | Derivados de 4-amino-5-fenil-7-ciclobutilpirrolo (2,3-d)pirimidina, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos derivados para la preparacion de una composicion farmaceutica |
WO2003024931A1 (fr) | 2001-09-14 | 2003-03-27 | Merck & Co., Inc. | Inhibiteurs de tyrosine kinase |
US7101884B2 (en) | 2001-09-14 | 2006-09-05 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
TWI259081B (en) * | 2001-10-26 | 2006-08-01 | Sugen Inc | Treatment of acute myeloid leukemia with indolinone compounds |
KR20090087139A (ko) | 2001-10-30 | 2009-08-14 | 노파르티스 아게 | Flt3 수용체 티로신 키나아제 활성의 억제제로서의 스타우로스포린 유도체 |
AU2002360753B2 (en) | 2001-12-27 | 2008-08-21 | Theravance, Inc. | Indolinone derivatives useful as protein kinase inhibitors |
PE20040522A1 (es) | 2002-05-29 | 2004-09-28 | Novartis Ag | Derivados de diarilurea dependientes de la cinasa de proteina |
MY141867A (en) | 2002-06-20 | 2010-07-16 | Vertex Pharma | Substituted pyrimidines useful as protein kinase inhibitors |
GB0215676D0 (en) | 2002-07-05 | 2002-08-14 | Novartis Ag | Organic compounds |
WO2004016597A2 (fr) | 2002-08-14 | 2004-02-26 | Vertex Pharmaceuticals Incorporated | Inhibiteurs de la proteine kinase et leurs utilisations |
EP1539754A4 (fr) | 2002-08-23 | 2009-02-25 | Novartis Vaccines & Diagnostic | Quinolinones de benzimidazole et leurs utilisations |
EP1566379A4 (fr) | 2002-10-29 | 2005-11-09 | Kirin Brewery | DERIVES DE QUINOLINE ET DE QUINAZOLINE INHIBANT L'AUTOPHOSPHORYLATION DE Flt3 ET COMPOSITIONS MEDICALES LES CONTENANT |
JP2006511616A (ja) | 2002-11-13 | 2006-04-06 | カイロン コーポレイション | 癌の処置方法およびその関連方法 |
CL2003002353A1 (es) | 2002-11-15 | 2005-02-04 | Vertex Pharma | Compuestos derivados de diaminotriazoles, inhibidores d ela proteina quinasa; composicion farmaceutica; procedimiento de preparacion; y su uso del compuesto en el tratamiento de enfermedades de desordenes alergicos, proliferacion, autoinmunes, condic |
US7226919B2 (en) | 2002-12-18 | 2007-06-05 | Vertex Pharmaceuticals Inc. | Compositions useful as inhibitors of protein kinases |
JP2007525460A (ja) * | 2003-04-25 | 2007-09-06 | オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド | c−fmsキナーゼ阻害剤 |
US20050113566A1 (en) | 2003-04-25 | 2005-05-26 | Player Mark R. | Inhibitors of C-FMS kinase |
US7427683B2 (en) | 2003-04-25 | 2008-09-23 | Ortho-Mcneil Pharmaceutical, Inc. | c-fms kinase inhibitors |
ES2611604T3 (es) * | 2004-10-22 | 2017-05-09 | Janssen Pharmaceutica Nv | Inhibidores de la c fms quinasa |
US20060281771A1 (en) * | 2005-06-10 | 2006-12-14 | Baumann Christian A | Synergistic modulation of flt3 kinase using aminoquinoline and aminoquinazoline kinase modulators |
US20060281788A1 (en) * | 2005-06-10 | 2006-12-14 | Baumann Christian A | Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor |
AU2006304897B2 (en) * | 2005-10-18 | 2012-07-12 | Janssen Pharmaceutica N.V. | Method of inhibiting FLT3 kinase |
CA2627830A1 (fr) * | 2005-11-03 | 2007-05-18 | Vertex Pharmaceuticals Incorporated | Aminopyrimidines utiles en tant qu'inhibiteurs de kinases |
CN101360740A (zh) * | 2005-11-16 | 2009-02-04 | 沃泰克斯药物股份有限公司 | 可用作激酶抑制剂的氨基嘧啶 |
-
2006
- 2006-10-17 AU AU2006304897A patent/AU2006304897B2/en not_active Ceased
- 2006-10-17 KR KR1020087011779A patent/KR101443651B1/ko active IP Right Grant
- 2006-10-17 EP EP06846103A patent/EP1951234A2/fr not_active Withdrawn
- 2006-10-17 NZ NZ595182A patent/NZ595182A/xx not_active IP Right Cessation
- 2006-10-17 JP JP2008536627A patent/JP2009511628A/ja not_active Withdrawn
- 2006-10-17 BR BRPI0617489-2A patent/BRPI0617489A2/pt not_active Application Discontinuation
- 2006-10-17 CN CN200680047813XA patent/CN101340909B/zh not_active Expired - Fee Related
- 2006-10-17 CA CA2626623A patent/CA2626623C/fr not_active Expired - Fee Related
- 2006-10-17 EA EA200801118A patent/EA200801118A1/xx unknown
- 2006-10-17 WO PCT/US2006/060028 patent/WO2007048088A2/fr active Application Filing
- 2006-10-17 US US11/550,077 patent/US7795279B2/en not_active Expired - Fee Related
- 2006-10-17 UA UAA200804647A patent/UA94719C2/ru unknown
-
2008
- 2008-04-08 IL IL190727A patent/IL190727A/en active IP Right Grant
- 2008-04-18 EC EC2008008387A patent/ECSP088387A/es unknown
- 2008-04-18 SV SV2008002880A patent/SV2008002880A/es unknown
- 2008-05-14 NO NO20082223A patent/NO20082223L/no not_active Application Discontinuation
- 2008-05-16 CR CR9984A patent/CR9984A/es unknown
- 2008-05-16 ZA ZA200804253A patent/ZA200804253B/xx unknown
- 2008-05-18 GT GT200800042A patent/GT200800042A/es unknown
-
2014
- 2014-03-06 JP JP2014044020A patent/JP2014129407A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
NZ595182A (en) | 2012-12-21 |
GT200800042A (es) | 2008-11-03 |
NO20082223L (no) | 2008-07-02 |
WO2007048088A3 (fr) | 2007-06-07 |
US20070149572A1 (en) | 2007-06-28 |
EP1951234A2 (fr) | 2008-08-06 |
AU2006304897B2 (en) | 2012-07-12 |
BRPI0617489A2 (pt) | 2011-07-26 |
KR20080064867A (ko) | 2008-07-09 |
SV2008002880A (es) | 2010-01-05 |
CR9984A (es) | 2008-09-09 |
UA94719C2 (ru) | 2011-06-10 |
JP2014129407A (ja) | 2014-07-10 |
IL190727A (en) | 2015-05-31 |
US7795279B2 (en) | 2010-09-14 |
KR101443651B1 (ko) | 2014-09-23 |
CN101340909B (zh) | 2012-01-11 |
CA2626623A1 (fr) | 2007-04-26 |
ZA200804253B (en) | 2009-11-25 |
ECSP088387A (es) | 2008-05-30 |
CN101340909A (zh) | 2009-01-07 |
WO2007048088A2 (fr) | 2007-04-26 |
EA200801118A1 (ru) | 2008-10-30 |
JP2009511628A (ja) | 2009-03-19 |
AU2006304897A1 (en) | 2007-04-26 |
IL190727A0 (en) | 2008-12-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2626623C (fr) | Methode d'inhibition de la kinase flt3 | |
CA2611474C (fr) | Modulation synergique de kinase flt3 kinase au moyen d'un inhibiteur flt3 et d'un inhibiteur de farnesyl transferase | |
CA2649755C (fr) | Procede d'inhibition de la kinase de c-kit | |
US9526731B2 (en) | Method of inhibiting C-KIT kinase | |
JP2009501135A (ja) | アルキルキノリン及びアルキルキナゾリンのキナーゼモジュレーター | |
JP2011502991A (ja) | 骨癌並びに骨癌に伴う骨喪失及び骨痛の処置又は予防のためのcfms阻害物質の使用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKLA | Lapsed |
Effective date: 20211018 |